West Pharmaceutical Services (NYSE:WST) Hits New 12-Month High at $159.21

West Pharmaceutical Services Inc. (NYSE:WST)’s stock price hit a new 52-week high during mid-day trading on Friday . The stock traded as high as $159.21 and last traded at $158.47, with a volume of 17000 shares traded. The stock had previously closed at $158.36.

Several research analysts recently issued reports on the company. Bank of America lowered West Pharmaceutical Services from a “neutral” rating to an “underperform” rating and set a $135.00 target price for the company. in a research report on Thursday, December 12th. ValuEngine lowered West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, Zacks Investment Research raised West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $160.00 target price for the company in a research report on Sunday, November 3rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $132.29.

The firm has a market capitalization of $11.58 billion, a P/E ratio of 56.40, a price-to-earnings-growth ratio of 3.24 and a beta of 1.24. The company has a current ratio of 3.00, a quick ratio of 2.31 and a debt-to-equity ratio of 0.17. The company has a 50-day moving average of $150.01 and a 200-day moving average of $142.49.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, October 24th. The medical instruments supplier reported $0.79 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.71 by $0.08. West Pharmaceutical Services had a return on equity of 16.66% and a net margin of 12.82%. The business had revenue of $456.10 million during the quarter, compared to analyst estimates of $450.03 million. During the same period last year, the company earned $0.76 EPS. West Pharmaceutical Services’s revenue for the quarter was up 5.6% compared to the same quarter last year. Research analysts predict that West Pharmaceutical Services Inc. will post 3.14 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, February 5th. Shareholders of record on Wednesday, January 22nd will be issued a dividend of $0.16 per share. This is an increase from West Pharmaceutical Services’s previous quarterly dividend of $0.15. This represents a $0.64 dividend on an annualized basis and a yield of 0.41%. The ex-dividend date is Tuesday, January 21st. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 22.78%.

A number of institutional investors have recently modified their holdings of the business. Wedbush Securities Inc. acquired a new stake in West Pharmaceutical Services during the 4th quarter worth about $204,000. Sciencast Management LP grew its holdings in West Pharmaceutical Services by 38.8% during the 4th quarter. Sciencast Management LP now owns 4,650 shares of the medical instruments supplier’s stock worth $701,000 after acquiring an additional 1,301 shares during the period. Cerebellum GP LLC grew its holdings in West Pharmaceutical Services by 22.1% during the 4th quarter. Cerebellum GP LLC now owns 3,736 shares of the medical instruments supplier’s stock worth $562,000 after acquiring an additional 676 shares during the period. IFM Investors Pty Ltd acquired a new stake in West Pharmaceutical Services during the 4th quarter worth about $768,000. Finally, DNB Asset Management AS acquired a new stake in West Pharmaceutical Services during the 4th quarter worth about $1,855,000. Hedge funds and other institutional investors own 90.21% of the company’s stock.

About West Pharmaceutical Services (NYSE:WST)

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, South Korea, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

Recommended Story: How is the discount rate different from the Federal Funds rate?

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.